{
  "paper_id": "PMC7583786",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583786/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Schematic presentation of the registry and study flow for patients with skin cancer with concomitant hematological malignancy.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e42/7583786/4b5808b94b3c/jitc-2020-000897f01.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e42/7583786/4b5808b94b3c/jitc-2020-000897f01.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e42/7583786/4b5808b94b3c/jitc-2020-000897f01.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e42/7583786/4b5808b94b3c/jitc-2020-000897f01.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e42/7583786/4b5808b94b3c/jitc-2020-000897f01.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC7583786/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e42/7583786/4b5808b94b3c/jitc-2020-000897f01.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Data analyzes for the comparator patient cohorts without concomitant hematological malignancy were done in August 2020.Results\nPatient characteristics\nA total of 84 patients with concomitant hematological malignancy were identified at 20 skin cancer centers according to the above described selection criteria; 52 patients with MM, 15 with cSCC, and 17 with MCC (table 1, figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Comparing the three skin cancer entities within the cohort of patients treated for non-resectable disease, the median PFS was 8.4 months (95% CI 3.9 to 12.8) for MM, 5.7 months (95% CI 0.7 to 10.7) for MCC, and only 4.0 months (95% CI 0.3 to 7.9) for cSCC (table 3; figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "1-year OS rates were 78.4% (MM), 47.4% (MCC), and 65.8% (cSCC) (table 3; figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Neither relevant survival differences were found between patients grouped according to the type of their hematological malignancy (figure 2C, D), nor to the presence or absence of a previous systemic treatment of this hematological malignancy (data not shown).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "P values were calculated using the log rank test.Comparison with real-world patient cohorts without hematological malignancy\nComparison of the ICI therapy outcome data of patients with concomitant hematological malignancy with real-world data of patient cohorts without hematological malignancy revealed no relevant differences for MM and MCC concerning PFS and OS on ICI treatment (see table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For cSCC, the PFS was significantly reduced in patients with a concomitant hematological malignancy as compared with patients without (median 4.0 months vs not reached; p=0.002; table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Herein, we found a significantly impaired PFS (p=0.002) for cSCC patients, but no relevant difference in survival for MM and MCC patients (figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Data analyzes for the comparator patient cohorts without concomitant hematological malignancy were done in August 2020.Results\nPatient characteristics\nA total of 84 patients with concomitant hematological malignancy were identified at 20 skin cancer centers according to the above described selection criteria; 52 patients with MM, 15 with cSCC, and 17 with MCC (table 1, figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Comparing the three skin cancer entities within the cohort of patients treated for non-resectable disease, the median PFS was 8.4 months (95% CI 3.9 to 12.8) for MM, 5.7 months (95% CI 0.7 to 10.7) for MCC, and only 4.0 months (95% CI 0.3 to 7.9) for cSCC (table 3; figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "1-year OS rates were 78.4% (MM), 47.4% (MCC), and 65.8% (cSCC) (table 3; figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Neither relevant survival differences were found between patients grouped according to the type of their hematological malignancy (figure 2C, D), nor to the presence or absence of a previous systemic treatment of this hematological malignancy (data not shown).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "P values were calculated using the log rank test.Comparison with real-world patient cohorts without hematological malignancy\nComparison of the ICI therapy outcome data of patients with concomitant hematological malignancy with real-world data of patient cohorts without hematological malignancy revealed no relevant differences for MM and MCC concerning PFS and OS on ICI treatment (see table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For cSCC, the PFS was significantly reduced in patients with a concomitant hematological malignancy as compared with patients without (median 4.0 months vs not reached; p=0.002; table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Herein, we found a significantly impaired PFS (p=0.002) for cSCC patients, but no relevant difference in survival for MM and MCC patients (figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Data analyzes for the comparator patient cohorts without concomitant hematological malignancy were done in August 2020.Results\nPatient characteristics\nA total of 84 patients with concomitant hematological malignancy were identified at 20 skin cancer centers according to the above described selection criteria; 52 patients with MM, 15 with cSCC, and 17 with MCC (table 1, figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Comparing the three skin cancer entities within the cohort of patients treated for non-resectable disease, the median PFS was 8.4 months (95% CI 3.9 to 12.8) for MM, 5.7 months (95% CI 0.7 to 10.7) for MCC, and only 4.0 months (95% CI 0.3 to 7.9) for cSCC (table 3; figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "1-year OS rates were 78.4% (MM), 47.4% (MCC), and 65.8% (cSCC) (table 3; figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Neither relevant survival differences were found between patients grouped according to the type of their hematological malignancy (figure 2C, D), nor to the presence or absence of a previous systemic treatment of this hematological malignancy (data not shown).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "P values were calculated using the log rank test.Comparison with real-world patient cohorts without hematological malignancy\nComparison of the ICI therapy outcome data of patients with concomitant hematological malignancy with real-world data of patient cohorts without hematological malignancy revealed no relevant differences for MM and MCC concerning PFS and OS on ICI treatment (see table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For cSCC, the PFS was significantly reduced in patients with a concomitant hematological malignancy as compared with patients without (median 4.0 months vs not reached; p=0.002; table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Herein, we found a significantly impaired PFS (p=0.002) for cSCC patients, but no relevant difference in survival for MM and MCC patients (figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Data analyzes for the comparator patient cohorts without concomitant hematological malignancy were done in August 2020.Results\nPatient characteristics\nA total of 84 patients with concomitant hematological malignancy were identified at 20 skin cancer centers according to the above described selection criteria; 52 patients with MM, 15 with cSCC, and 17 with MCC (table 1, figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Comparing the three skin cancer entities within the cohort of patients treated for non-resectable disease, the median PFS was 8.4 months (95% CI 3.9 to 12.8) for MM, 5.7 months (95% CI 0.7 to 10.7) for MCC, and only 4.0 months (95% CI 0.3 to 7.9) for cSCC (table 3; figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "1-year OS rates were 78.4% (MM), 47.4% (MCC), and 65.8% (cSCC) (table 3; figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Neither relevant survival differences were found between patients grouped according to the type of their hematological malignancy (figure 2C, D), nor to the presence or absence of a previous systemic treatment of this hematological malignancy (data not shown).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "P values were calculated using the log rank test.Comparison with real-world patient cohorts without hematological malignancy\nComparison of the ICI therapy outcome data of patients with concomitant hematological malignancy with real-world data of patient cohorts without hematological malignancy revealed no relevant differences for MM and MCC concerning PFS and OS on ICI treatment (see table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For cSCC, the PFS was significantly reduced in patients with a concomitant hematological malignancy as compared with patients without (median 4.0 months vs not reached; p=0.002; table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Herein, we found a significantly impaired PFS (p=0.002) for cSCC patients, but no relevant difference in survival for MM and MCC patients (figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Data analyzes for the comparator patient cohorts without concomitant hematological malignancy were done in August 2020.Results\nPatient characteristics\nA total of 84 patients with concomitant hematological malignancy were identified at 20 skin cancer centers according to the above described selection criteria; 52 patients with MM, 15 with cSCC, and 17 with MCC (table 1, figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Comparing the three skin cancer entities within the cohort of patients treated for non-resectable disease, the median PFS was 8.4 months (95% CI 3.9 to 12.8) for MM, 5.7 months (95% CI 0.7 to 10.7) for MCC, and only 4.0 months (95% CI 0.3 to 7.9) for cSCC (table 3; figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "1-year OS rates were 78.4% (MM), 47.4% (MCC), and 65.8% (cSCC) (table 3; figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Neither relevant survival differences were found between patients grouped according to the type of their hematological malignancy (figure 2C, D), nor to the presence or absence of a previous systemic treatment of this hematological malignancy (data not shown).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "P values were calculated using the log rank test.Comparison with real-world patient cohorts without hematological malignancy\nComparison of the ICI therapy outcome data of patients with concomitant hematological malignancy with real-world data of patient cohorts without hematological malignancy revealed no relevant differences for MM and MCC concerning PFS and OS on ICI treatment (see table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For cSCC, the PFS was significantly reduced in patients with a concomitant hematological malignancy as compared with patients without (median 4.0 months vs not reached; p=0.002; table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Herein, we found a significantly impaired PFS (p=0.002) for cSCC patients, but no relevant difference in survival for MM and MCC patients (figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Data analyzes for the comparator patient cohorts without concomitant hematological malignancy were done in August 2020.Results\nPatient characteristics\nA total of 84 patients with concomitant hematological malignancy were identified at 20 skin cancer centers according to the above described selection criteria; 52 patients with MM, 15 with cSCC, and 17 with MCC (table 1, figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Comparing the three skin cancer entities within the cohort of patients treated for non-resectable disease, the median PFS was 8.4 months (95% CI 3.9 to 12.8) for MM, 5.7 months (95% CI 0.7 to 10.7) for MCC, and only 4.0 months (95% CI 0.3 to 7.9) for cSCC (table 3; figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "1-year OS rates were 78.4% (MM), 47.4% (MCC), and 65.8% (cSCC) (table 3; figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Neither relevant survival differences were found between patients grouped according to the type of their hematological malignancy (figure 2C, D), nor to the presence or absence of a previous systemic treatment of this hematological malignancy (data not shown).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "P values were calculated using the log rank test.Comparison with real-world patient cohorts without hematological malignancy\nComparison of the ICI therapy outcome data of patients with concomitant hematological malignancy with real-world data of patient cohorts without hematological malignancy revealed no relevant differences for MM and MCC concerning PFS and OS on ICI treatment (see table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For cSCC, the PFS was significantly reduced in patients with a concomitant hematological malignancy as compared with patients without (median 4.0 months vs not reached; p=0.002; table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Herein, we found a significantly impaired PFS (p=0.002) for cSCC patients, but no relevant difference in survival for MM and MCC patients (figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Data analyzes for the comparator patient cohorts without concomitant hematological malignancy were done in August 2020.Results\nPatient characteristics\nA total of 84 patients with concomitant hematological malignancy were identified at 20 skin cancer centers according to the above described selection criteria; 52 patients with MM, 15 with cSCC, and 17 with MCC (table 1, figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Comparing the three skin cancer entities within the cohort of patients treated for non-resectable disease, the median PFS was 8.4 months (95% CI 3.9 to 12.8) for MM, 5.7 months (95% CI 0.7 to 10.7) for MCC, and only 4.0 months (95% CI 0.3 to 7.9) for cSCC (table 3; figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "1-year OS rates were 78.4% (MM), 47.4% (MCC), and 65.8% (cSCC) (table 3; figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Neither relevant survival differences were found between patients grouped according to the type of their hematological malignancy (figure 2C, D), nor to the presence or absence of a previous systemic treatment of this hematological malignancy (data not shown).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "P values were calculated using the log rank test.Comparison with real-world patient cohorts without hematological malignancy\nComparison of the ICI therapy outcome data of patients with concomitant hematological malignancy with real-world data of patient cohorts without hematological malignancy revealed no relevant differences for MM and MCC concerning PFS and OS on ICI treatment (see table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For cSCC, the PFS was significantly reduced in patients with a concomitant hematological malignancy as compared with patients without (median 4.0 months vs not reached; p=0.002; table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Herein, we found a significantly impaired PFS (p=0.002) for cSCC patients, but no relevant difference in survival for MM and MCC patients (figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Data analyzes for the comparator patient cohorts without concomitant hematological malignancy were done in August 2020.Results\nPatient characteristics\nA total of 84 patients with concomitant hematological malignancy were identified at 20 skin cancer centers according to the above described selection criteria; 52 patients with MM, 15 with cSCC, and 17 with MCC (table 1, figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Comparing the three skin cancer entities within the cohort of patients treated for non-resectable disease, the median PFS was 8.4 months (95% CI 3.9 to 12.8) for MM, 5.7 months (95% CI 0.7 to 10.7) for MCC, and only 4.0 months (95% CI 0.3 to 7.9) for cSCC (table 3; figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "1-year OS rates were 78.4% (MM), 47.4% (MCC), and 65.8% (cSCC) (table 3; figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Neither relevant survival differences were found between patients grouped according to the type of their hematological malignancy (figure 2C, D), nor to the presence or absence of a previous systemic treatment of this hematological malignancy (data not shown).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "P values were calculated using the log rank test.Comparison with real-world patient cohorts without hematological malignancy\nComparison of the ICI therapy outcome data of patients with concomitant hematological malignancy with real-world data of patient cohorts without hematological malignancy revealed no relevant differences for MM and MCC concerning PFS and OS on ICI treatment (see table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For cSCC, the PFS was significantly reduced in patients with a concomitant hematological malignancy as compared with patients without (median 4.0 months vs not reached; p=0.002; table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Herein, we found a significantly impaired PFS (p=0.002) for cSCC patients, but no relevant difference in survival for MM and MCC patients (figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Results\nPatient characteristics\nA total of 84 patients with concomitant hematological malignancy were identified at 20 skin cancer centers according to the above described selection criteria; 52 patients with MM, 15 with cSCC, and 17 with MCC (table 1, figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Comparing the three skin cancer entities within the cohort of patients treated for non-resectable disease, the median PFS was 8.4 months (95% CI 3.9 to 12.8) for MM, 5.7 months (95% CI 0.7 to 10.7) for MCC, and only 4.0 months (95% CI 0.3 to 7.9) for cSCC (table 3; figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "1-year OS rates were 78.4% (MM), 47.4% (MCC), and 65.8% (cSCC) (table 3; figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Neither relevant survival differences were found between patients grouped according to the type of their hematological malignancy (figure 2C, D), nor to the presence or absence of a previous systemic treatment of this hematological malignancy (data not shown).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "P values were calculated using the log rank test.Comparison with real-world patient cohorts without hematological malignancy\nComparison of the ICI therapy outcome data of patients with concomitant hematological malignancy with real-world data of patient cohorts without hematological malignancy revealed no relevant differences for MM and MCC concerning PFS and OS on ICI treatment (see table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For cSCC, the PFS was significantly reduced in patients with a concomitant hematological malignancy as compared with patients without (median 4.0 months vs not reached; p=0.002; table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Patient characteristics\nA total of 84 patients with concomitant hematological malignancy were identified at 20 skin cancer centers according to the above described selection criteria; 52 patients with MM, 15 with cSCC, and 17 with MCC (table 1, figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "A total of 84 patients with concomitant hematological malignancy were identified at 20 skin cancer centers according to the above described selection criteria; 52 patients with MM, 15 with cSCC, and 17 with MCC (table 1, figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Comparing the three skin cancer entities within the cohort of patients treated for non-resectable disease, the median PFS was 8.4 months (95% CI 3.9 to 12.8) for MM, 5.7 months (95% CI 0.7 to 10.7) for MCC, and only 4.0 months (95% CI 0.3 to 7.9) for cSCC (table 3; figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "1-year OS rates were 78.4% (MM), 47.4% (MCC), and 65.8% (cSCC) (table 3; figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Neither relevant survival differences were found between patients grouped according to the type of their hematological malignancy (figure 2C, D), nor to the presence or absence of a previous systemic treatment of this hematological malignancy (data not shown).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Comparing the three skin cancer entities within the cohort of patients treated for non-resectable disease, the median PFS was 8.4 months (95% CI 3.9 to 12.8) for MM, 5.7 months (95% CI 0.7 to 10.7) for MCC, and only 4.0 months (95% CI 0.3 to 7.9) for cSCC (table 3; figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "1-year OS rates were 78.4% (MM), 47.4% (MCC), and 65.8% (cSCC) (table 3; figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Neither relevant survival differences were found between patients grouped according to the type of their hematological malignancy (figure 2C, D), nor to the presence or absence of a previous systemic treatment of this hematological malignancy (data not shown).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Comparison with real-world patient cohorts without hematological malignancy\nComparison of the ICI therapy outcome data of patients with concomitant hematological malignancy with real-world data of patient cohorts without hematological malignancy revealed no relevant differences for MM and MCC concerning PFS and OS on ICI treatment (see table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For cSCC, the PFS was significantly reduced in patients with a concomitant hematological malignancy as compared with patients without (median 4.0 months vs not reached; p=0.002; table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Comparison of the ICI therapy outcome data of patients with concomitant hematological malignancy with real-world data of patient cohorts without hematological malignancy revealed no relevant differences for MM and MCC concerning PFS and OS on ICI treatment (see table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "For cSCC, the PFS was significantly reduced in patients with a concomitant hematological malignancy as compared with patients without (median 4.0 months vs not reached; p=0.002; table 3, figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Herein, we found a significantly impaired PFS (p=0.002) for cSCC patients, but no relevant difference in survival for MM and MCC patients (figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Herein, we found a significantly impaired PFS (p=0.002) for cSCC patients, but no relevant difference in survival for MM and MCC patients (figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 1,
    "claims_count": 76,
    "images_downloaded": 1,
    "tables_filtered": 44
  }
}